[ad_1]
The manufacturer, Gilead, questioned the results of the United Nations World Health Organization (WHO) investigation that a drug called remdesivir does not help people hospitalized due to a new coronavirus disease.
The US company told Reuters it thought the WHO research data was “contradictory, rushed” and that previous research had already confirmed the drug’s benefits, writes MTI. According to a WHO report on Thursday, their study called Solidarity showed that remdesivir had little to no effect on the length of hospitalization and mortality of respiratory patients with Covid-19 during the 28-day study period.
This antiviral drug is one of those used to treat the coronavirus infection of the president of the United States, Donald Trump. Previous research has shown that it reduces recovery time. The WHO conducted the study with 11,266 adult patients from more than 30 countries. The evidence obtained was convincing
Said the world organization.
According to Gilead, studies with remdesivir have shown that treatment reduces the time it takes to recover from Covid-19.
Data published by the WHO are inconsistent, while strong evidence from studies in peer-reviewed, peer-reviewed, and peer-reviewed scientific journals supports the clinical efficacy of rendesivir.
Said the company.
[ad_2]
